VAS and LI
CS | Celecoxib | Placebo | |||||||
n | Mean (SE)* | p Value† | n | Mean (SE)* | p Value† | n | Mean (SE)* | p Value‡ | |
VAS | |||||||||
Baseline | 199 | 71.2 (0.8) | 195 | 70.0 (0.8) | 205 | 70.2 (0.8) | |||
Day 30 | 195 | 49.4 (1.5) | 0.869 | 195 | 46.9 (1.5) | 0.159 | 204 | 49.7 (1.4) | 0.309 |
Day 91 | 179 | 39.4 (1.7) | 0.429 | 182 | 38.3 (1.7) | 0.213 | 188 | 41.2 (1.6) | 0.450 |
Day 182 | 160 | 28.6 (1.8) | 0.001 | 173 | 30.5 (1.7) | 0.009 | 172 | 36.8 (1.7) | 0.002 |
LI | |||||||||
Baseline | 199 | 11.8 (0.2) | 195 | 11.6 (0.2) | 205 | 11.8 (0.2) | |||
Day 30 | 195 | 9.6 (0.3) | 0.714 | 195 | 9.1 (0.3) | 0.045 | 204 | 9.8 (0.3) | 0.105 |
Day 91 | 179 | 8.1 (0.3) | 0.050 | 182 | 8.0 (0.3) | 0.027 | 188 | 8.8 (0.3) | 0.052 |
Day 182 | 160 | 7.1 (0.3) | 0.023 | 173 | 7.0 (0.3) | 0.015 | 172 | 8.0 (0.3) | 0.024 |
*Estimated mean and SE from a mixed-model analysis.
†Compared with placebo.
‡Comparing three treatment groups.
LI, Lequesne Index; VAS, Visual Analogue Scale.